brain/
sourcestock-market

GLP-1 Supply Chain Second-Order Beneficiaries — June 2026

GLP-1 demand surge → peptide API/fill-finish/device/distribution capacity crunch → highest-conviction picks-and-shovels beneficiaries are Bachem (BANB), West Pharma (WST), Stevanato Group (STVN), and Ypsomed (YPSN), with CordenPharma and Lonza as unlisted but structurally important players

Source

GLP-1 Supply Chain Second-Order Beneficiaries — June 2026

Research summary

GLP-1 drugs (Ozempic/Wegovy/semaglutide by Novo Nordisk; Mounjaro/Zepbound/tirzepatide by Eli Lilly) have reached ~32 million US users as of late 2025 (~1 in 8 US adults). Shortages officially resolved (semaglutide Feb 2025; tirzepatide confirmed resolved by mid-2025), but real-world availability is still uneven at maintenance doses. The FDA is now moving to permanently block large-scale 503B compounding of all three main GLP-1 APIs, removing the compounding safety valve and forcing demand entirely onto branded supply chains. The global GLP-1/incretin market is projected to reach $200 billion by 2030 (J.P. Morgan), with Lilly's Q3 2025 GLP-1 sales alone hitting $10 billion (52% of quarterly revenue). This creates deep, multi-year demand across the entire manufacturing stack.

Supply/demand status as of June 2026

  • Ozempic: Widely available; 2 mg strength has intermittent delays at high-volume locations. (source)
  • Wegovy: Mostly available; lower titration doses more readily stocked than maintenance doses.
  • Mounjaro: All strengths generally in stock.
  • Zepbound: Both pen and vial formats available.
  • FDA officially ended semaglutide shortage February 2025; tirzepatide shortage resolved by mid-2025. (source)
  • Compounding pharmacies (503B outsourcing facilities) being permanently excluded from producing semaglutide, tirzepatide, and liraglutide; comment period ends June 29, 2026. (source)
  • Net effect: Compounding ban removes ~10-20% of market supply over the next 12 months, driving demand back to branded supply chains during a period when new capacity is still ramping. This is a near-term bullish catalyst for every tier of the supply chain.

Causal chain map

Chain 1: GLP-1 demand surge → peptide API bottleneck → Bachem (BANB.SW)

Mechanism: GLP-1 drugs are injectable peptides. Semaglutide and tirzepatide are synthesized via solid-phase peptide synthesis (SPPS). The API manufacturing step is rate-limiting — it requires specialized large-capacity SPPS reactors, purification, and freeze-drying infrastructure that cannot be repurposed from standard pharma. As Novo and Lilly scale, they pull on a small number of validated peptide CDMOs.

Bachem (SIX: BANB) is the world's largest pure-play peptide API CDMO and the clearest direct beneficiary:

  • FY2025 revenue: CHF 695.1 million (+14.8% YoY; +19.2% in local currencies). (source)
  • H1 2025: CHF 313M (+30.2% vs H1 2024); EBITDA margin 29.1% (up from 23.1%).
  • 2026 target: >CHF 1 billion revenue, >30% EBITDA margin — a 65%+ two-year revenue growth.
  • Building K (new large-scale SPPS facility): Phase 1 inspected by Swiss Swissmedic at end-2025; commercial production ramping in 2026. Phase 2 still under construction. Building K is the key enabler for the 2026 revenue target. (source)
  • Peptide API market volume projected to grow from 265 metric tonnes (2025) to 855 MT by 2031 at 21.72% CAGR — volume growth driven by manufacturing scale, not just new drug approvals. (source)

PolyPeptide Group (SIX: PPGN) is the second-largest pure-play peer, also publicly listed. Less dominant than Bachem; worth monitoring.

CordenPharma (private, ~€960M FY2025 revenue) is rapidly consolidating:

  • Announced acquisition of AmbioPharm (US peptide CDMO, ~400 employees, North Augusta SC + Shanghai) on May 27, 2026. (source)
  • In March 2025, signed a multi-year, $150 million manufacturing agreement with Viking Therapeutics for API + finished product supply for Viking's obesity drug candidate. (source)
  • CordenPharma is private, so the direct trade is VKTX (Viking Therapeutics) + Bachem as the public proxies; CordenPharma itself is not investable.

WuXi AppTec / WuXi TIDES (China-listed, geopolitical risk):

  • SPPS capacity exceeded 100,000 liters by end-2025 (tripled from base); targeting >130,000 liters by end-2026. (source)
  • Multiple FDA inspections passed with no observations (March 2025). (source)
  • Caveat: Biosecure Act risk makes WuXi a regulatory wildcard for US-market revenue.

Chain 2: GLP-1 injectable scale → fill-finish capacity → Stevanato Group (STVN)

Mechanism: Every injectable GLP-1 dose needs a primary container — a prefilled syringe, glass vial, or cartridge — and Stevanato makes the highest-performing versions (Nexa prefilled syringes, EZ-fill cartridges). Fill-finish CDMOs sterilize and fill these containers. Both the container hardware and the fill-finish service are in high demand.

Stevanato Group (NYSE: STVN) is the highest-conviction listed beneficiary in the fill-finish/containment layer:

  • GLP-1 revenue grew >50% in 2025 vs 2024; GLP-1 = ~19-20% of total 2025 revenue. (source)
  • Fastest-growing product: Nexa prefilled syringes, driven primarily by GLP-1.
  • Customer base for high-value prefilled syringes grew >40% in 2025.
  • 2026 GLP-1 growth guidance: "mid-teens" percentage. Full-year 2026 revenue guidance: €1.260–€1.290 billion, with high-value solutions ~47-48% of revenue.
  • CapEx 2025: €294.9M (89% deployed for growth), with Fishers, Indiana plant targeting commercial activities by end-2026 / early 2027. Latina, Italy adding syringe capacity and EZ-fill cartridge lines. (source)
  • Management projects injectable GLP-1s will remain ~70% of total GLP-1 volume even as oral pills grow.

Catalent / Novo Nordisk's fill-finish strategy (key structural change):

  • Novo Holdings acquired Catalent for $16.5 billion (completed December 2024); Novo Nordisk then acquired three Catalent fill-finish sites (Anagni Italy, Bloomington Indiana, Brussels Belgium) from Novo Holdings for $11 billion. (source)
  • These three sites are now captive to Novo Nordisk. Eli Lilly CEO publicly complained this could damage competitors' access to fill-finish capacity. (source)
  • Implication for STVN: Lilly and other GLP-1 developers (Viking, Merck, Sanofi, etc.) who cannot use Novo's captured Catalent sites must go elsewhere — i.e., to Stevanato, Lonza, and other independents. This is structurally bullish for STVN's fill-finish contracted volumes over 2026-2028.

Lonza Group (SWX: LONN) also does fill-finish and peptide manufacturing:

  • Completed peptide manufacturing expansion at Visp, Switzerland in October 2024, including continuous flow manufacturing technology. (source)
  • Less pure-play than Bachem; harder to isolate GLP-1 contribution. Revenue from GLP-1 programs not separately disclosed.

Chain 3: GLP-1 injectable scale → elastomeric container components → West Pharmaceutical Services (WST)

Mechanism: Every injectable vial and prefilled syringe needs an elastomeric stopper, seal, or plunger that West manufactures. These are consumables — every dose uses them. West's high-value products (HVP) line serves GLP-1 specifically.

West Pharmaceutical Services (NYSE: WST):

  • GLP-1 represented 17% of net sales in full-year 2025; grew ~50% YoY (consistent across Q3 and Q4 reports). (source)
  • GLP-1 elastomers were 10% of total revenues in Q4 2025; GLP-1 contract manufacturing was 7% of Q4 2025 revenues.
  • Q1 2026: revenues grew 15% organically, led by HVP components with double-digit growth in GLP-1 and non-GLP-1 products. (source)
  • Full-year 2026 guidance: $3.295B–$3.350B revenues, organic growth 5-7%, HVP components growing high-single-digit to low-double-digit organically. GLP-1 alone forecast to contribute ~+1 percentage point to organic growth (conservative assumption per management). (source)
  • Management explicitly stated that "eight of ten patients using oral GLP-1s are new to the market" — oral pills are expanding total GLP-1 user population, not cannibalizing injectables, which protects WST's elastomer volume.

Chain 4: GLP-1 injectable scale → auto-injector / pen device bottleneck → Ypsomed (YPSN)

Mechanism: Wegovy, Ozempic, Mounjaro, and Zepbound are all delivered via auto-injector pens or prefilled injection devices. These are high-precision molded plastic devices with complex spring/drive mechanisms — not interchangeable commodity parts. Novo and Lilly either make devices in-house or outsource to specialists.

Ypsomed AG (SWX: YPSN) is the most direct publicly traded device beneficiary:

  • Signed a supply agreement with Novo Nordisk to produce large quantities of YpsoMate 1mL autoinjectors for GLP-1 drugs. (source)
  • Novo Nordisk funded "a significant part of the investment" for Ypsomed's new production infrastructure (new facilities in China and Germany). (source)
  • Commercial deliveries to Novo began in 2025, contributing to Ypsomed FY2025-2026 commercial sales. Ypsomed is private-company-like in its conservatism about disclosures but is publicly listed (SIX).
  • GLP-1 Autoinjector & Pen Injector market projected at 15.6% CAGR 2026-2035. (source)

SHL Medical (private, Taiwanese-owned):

  • ~25% global autoinjector market share; ~90% of revenue from autoinjectors. (source)
  • Opened a $220 million fully automated facility in North Charleston, SC in 2025. Not listed; but its parent (SHL Holdings) is investable via Taiwanese market.
  • Direct exposure to GLP-1 device ramp-up but no clean US-listed ticker.

Owen Mumford (UK, private) + Embecta (EMBC):

  • In March 2026, Embecta (NYSE: EMBC) announced acquisition of Owen Mumford for up to £150M plus performance payments tied to the Aidaptus next-gen autoinjector platform. (source)
  • This deal gives Embecta (spun out of BD) direct exposure to the GLP-1 device ecosystem via Owen Mumford's platform — a watch item.

Chain 5: GLP-1 prescription volume surge → specialty pharmaceutical distribution → Cencora (COR) and McKesson (MCK)

Mechanism: The major wholesale drug distributors move the physical product from manufacturer to pharmacy. As GLP-1 volumes grow, distribution revenue grows in proportion.

Cencora, Inc. (NYSE: COR) (formerly AmerisourceBergen):

  • Healthcare Solutions revenue: $74.0B in Q1 FY2025 (+13.6% YoY), $68.3B Q2 (+11.4%), $72.9B Q3 (+8.5%) — all driven in part by GLP-1 volume. (source)
  • GLP-1 (diabetes/weight-loss class) explicitly cited as a primary revenue driver every quarter.
  • Note: Cencora is a high-volume, low-margin distributor. GLP-1 is a tailwind on revenue but margin uplift is modest compared to device/API plays.

McKesson (NYSE: MCK):

  • US Pharmaceutical Segment revenues: $90.0B for FY2025 (+25%), driven partly by GLP-1 volume growth and specialty pharmaceutical distribution. (source)
  • Also benefits from cold-chain logistics requirements for injectable GLP-1s (refrigerated 2-8°C throughout supply chain).

Cold-chain nuance: Injectable GLP-1s require refrigerated 2-8°C distribution. Oral GLP-1s (orforglipron/Foundayo) are room-temperature small molecules — as oral adoption grows, cold-chain demand per-dose decreases. However, total GLP-1 prescription volume growing 20%+ annually more than offsets format shift. No pure-play cold chain public company clearly disaggregates GLP-1 cold-chain revenue.

Oral GLP-1 pills — supply chain implications and risk to injectable chain

Foundayo (orforglipron) by Eli Lilly launched April 6, 2026 — first oral non-peptide GLP-1. (source)

Key supply chain implications:

  1. No cold chain required: Small molecule; room temperature stable. Removes distribution cold-chain requirement as oral share grows.
  2. No peptide API manufacturing: Orforglipron is a non-peptide small molecule; it does NOT use SPPS or peptide CDMOs. This is a long-run risk for Bachem/PolyPeptide if oral GLP-1s take substantial share.
  3. No injectable device: Oral pills don't need auto-injectors. Long-run risk for Ypsomed/West/Stevanato if injectables lose share.
  4. Lilly management's mitigation: Lilly is building a dedicated orforglipron API plant in Huntsville, AL (2026+) — benefits small-molecule CDMOs, not peptide CDMOs.
  5. West Pharma's view: Management explicitly countered the cannibalization thesis: "eight of ten patients using oral GLP-1s are new to the market" — oral pills are expanding the total patient pool, not displacing injectables.
  6. STVN's view: 70% injectable / 30% oral split forecast to be stable for the foreseeable future.

Conviction scoring for supply chain tickers

TickerLayerGLP-1 Revenue ShareGrowth RateCausal Chain ClarityRiskConviction
BANB.SW (Bachem)Peptide APINot disclosed, but ~50-70% estimated+14.8% FY2025; targeting +40% by 2026Very high — only pure-play listed peptide API CDMOBuilding K ramp risk; WuXi competitionHIGH
STVN (Stevanato)Primary containers / fill-finish~19-20% FY2025+50% GLP-1 revenue in 2025High — named fastest-growing productOral shift risk long-termHIGH
WST (West Pharma)Elastomers / container components17% FY2025~50% FY2025 GLP-1 growthHigh — consumable per-dose, documented in earningsMature multiple; oral shift riskMEDIUM-HIGH
YPSN (Ypsomed)Auto-injectors / pensUndisclosedMaterial FY2025-2026 contributionHigh — named Novo Nordisk partnerPrivate-like disclosure; Novo concentrationMEDIUM-HIGH
COR (Cencora)Specialty distributionUndisclosed (large but diluted)+8-14% quarterly; GLP-1 cited every quarterMedium — volume tailwind, margin thinOral shift reduces cold-chain; margin compressionMEDIUM
MCK (McKesson)Specialty distributionUndisclosed (large but diluted)+25% FY2025 segmentMedium — same as CencoraSame risks as CORMEDIUM

Key falsifiers to watch

  1. Oral GLP-1 market share accelerates beyond 30% by 2027 → damages Bachem (no peptide needed), STVN (fewer syringes), WST (fewer elastomers), Ypsomed (no devices). Monitor Foundayo prescription tracking data quarterly.
  2. Biosecure Act passes and restricts WuXi AppTec → could redirect peptide API contracts to Bachem/CordenPharma (bullish), or create supply disruption (supply shock).
  3. Building K ramp fails or is delayed at Bachem → 2026 revenue target missed; stock re-rates lower. Watch CHF 1B target vs. actual at H1 2026 report.
  4. Novo Nordisk Wegovy demand disappoints (e.g., reimbursement rollbacks, clinical setbacks on cardiovascular label) → reduces entire supply chain pull.
  5. Compounding pharmacy legal challenges succeed → restores compounding supply valve, reduces branded demand.

Sources

Referenced by
Mechanisms
GLP-1 demand surge → four-layer manufacturing bottleneck → Bachem / Stevanato / West Pharma / Ypsomed
Entities
Bachem Holding AG (BANB.SW)Stevanato Group (NYSE: STVN)West Pharmaceutical Services (NYSE: WST)Ypsomed AG (SWX: YPSN)
brain — research vault